Breast Cancer Awareness, Part 3: I’ve Been Diagnosed โ What Now?
๐ Breast Cancer Awareness ยท Part 3 of 4
If you’re reading this because you โ or someone you love โ just heard the words “you have breast cancer,” first take a breath. That diagnosis is frightening, but it is also, for the great majority of women, a highly treatable one. Let me walk you calmly through what treatment actually looks like, so the unknown feels a little less overwhelming.
There is no single “breast cancer treatment” โ your plan is built specifically for your cancer, based on its type, size, stage, and the receptor status we discussed in Part 1. Care is directed by a team (surgeon, medical oncologist, radiation oncologist, and others). Here’s the landscape, in plain language.
The building blocks of treatment
Most treatment plans combine some of these, in an order tailored to you:
- Surgery โ removing the tumor, either breast-conserving (lumpectomy) or mastectomy, often with evaluation of the lymph nodes.
- Radiation โ targeted treatment to reduce the chance of the cancer returning locally, common after lumpectomy.
- Systemic therapy โ treatments that work throughout the body: endocrine (anti-hormone) therapy, chemotherapy, and targeted drugs (like HER2-directed therapy). This is where we’ll spend most of our time, because it’s where the most questions arise.
Endocrine (anti-hormone) therapy: the cornerstone for HR-positive cancer
Remember from Part 1 that about 3 in 4 breast cancers are hormone-receptor-positive โ they use estrogen as fuel. For these, one of the most powerful tools we have is endocrine therapy: medication that cuts off that fuel supply, dramatically lowering the risk of recurrence. It’s typically taken for 5 to 10 years, and it’s one of the great success stories of breast cancer care. There are two main approaches, and which one you get depends largely on whether you’re pre- or post-menopausal.
Tamoxifen
Tamoxifen is a selective estrogen receptor modulator โ it blocks estrogen’s effect on breast tissue, but acts a bit like estrogen in some other tissues. It works in both pre- and post-menopausal women, which makes it the mainstay for younger women. Adjuvant tamoxifen reduces the risk of dying from breast cancer at 15 years by about a third.
| Tamoxifen โ benefits | Tamoxifen โ side effects |
|---|---|
| Works in premenopausal and postmenopausal women; substantially cuts recurrence and mortality; protects bone (mild estrogen-like effect on the skeleton); may improve cholesterol. | Hot flashes and night sweats; small increased risk of blood clots; small increased risk of uterine (endometrial) cancer โ so any abnormal bleeding must be reported; vaginal dryness or discharge; mood changes. |
Aromatase inhibitors (AIs)
Aromatase inhibitors (anastrozole, letrozole, exemestane) work differently โ they block the enzyme that makes estrogen in body tissues. They only work when the ovaries aren’t the main estrogen source, so they’re used in postmenopausal women (or in premenopausal women combined with ovarian suppression). In postmenopausal women, AIs are modestly more effective than tamoxifen at preventing recurrence.
| Aromatase inhibitors โ benefits | Aromatase inhibitors โ side effects |
|---|---|
| Modestly more effective than tamoxifen at preventing recurrence in postmenopausal women; no increased risk of uterine cancer or blood clots. | Bone loss / osteoporosis and higher fracture risk (the big one โ see below); joint and muscle aches (very common); hot flashes; vaginal dryness; sometimes cholesterol changes. |
So why one versus the other?
In short: menopausal status and side-effect trade-offs. Premenopausal women generally start with tamoxifen (or an AI plus ovarian suppression for higher-risk disease). Postmenopausal women are often offered an AI for its slight edge in preventing recurrence โ unless bone loss, joint pain, or other factors make tamoxifen a better fit. The two have mirror-image side-effect profiles: tamoxifen protects bone but carries small clot/uterine risks; AIs avoid those but cause bone loss and joint aches. There’s no universally “better” drug โ there’s the better drug for you, and it’s a shared decision with your oncologist. Many women also switch between them over the treatment course.
What about chemotherapy โ do I need it?
This is one of the biggest fears, so let me be clear: not everyone with breast cancer needs chemotherapy. In fact, many women with early-stage, hormone-positive cancer do not. Chemo is used when the benefit of attacking any stray cancer cells throughout the body outweighs its costs โ generally in more aggressive or more advanced disease.
Crucially, we no longer guess. For many early-stage, HR-positive cancers, a tumor gene-expression test (such as Oncotype DX) analyzes the biology of your specific tumor and gives a recurrence score that predicts whether chemotherapy would actually add benefit. This has spared a great many women from chemotherapy they didn’t need โ a real advance. Chemo is more clearly indicated for triple-negative and HER2-positive cancers, and for larger or node-positive disease. When it’s needed, it’s given for good reason; when it’s not, modern testing can often reassure you of that.
Protecting your bones during treatment
This is where my world as a menopause physician intersects directly with cancer care โ and where you should advocate for yourself. Because aromatase inhibitors (and ovarian suppression, and chemo-induced menopause) sharply lower estrogen, they accelerate bone loss and raise fracture risk. Bone health is a standard, essential part of a good treatment plan โ not an afterthought.
What good bone care looks like during endocrine therapy
- Baseline and periodic DEXA bone density scans to monitor for loss.
- Adequate calcium and vitamin D (see our earlier bone-health posts).
- Weight-bearing and resistance exercise โ strength training to protect bone and muscle.
- Bone-protecting medication when indicated โ bisphosphonates (like zoledronic acid) or denosumab. Notably, in postmenopausal women these drugs do double duty: they protect bone and some evidence suggests they may reduce cancer recurrence in bone.
Follow-up: life after the main treatment
Finishing active treatment doesn’t mean you’re on your own. Survivorship care typically includes regular visits with your oncology team, ongoing mammograms (and imaging as indicated), staying on your endocrine therapy as prescribed, bone monitoring, and attention to the whole of your wellbeing โ physical and emotional. Managing the side effects of treatment well is part of helping you not just survive, but live fully.
Ending on hope: you can still find relief from menopausal symptoms
Here’s the part I most want you to carry with you, because it’s where so many women suffer needlessly and silently. The treatments that save your life โ especially the anti-estrogen therapies โ often cause menopausal symptoms: hot flashes, night sweats, and vaginal dryness. For years, women were told to simply endure them. That is no longer true. You have real, effective, and safe options.
For hot flashes & night sweats (non-hormonal)
Several non-hormonal treatments genuinely work, even while you’re on breast cancer therapy:
- The newer “NK3” medications โ fezolinetant (Veozah) and elinzanetant (Lynkuet, FDA-approved in October 2025). These target the brain’s temperature center directly. Notably, elinzanetant is the first non-hormonal drug specifically shown to reduce hot flashes in women taking tamoxifen or an aromatase inhibitor โ a genuine breakthrough for survivors.
- Certain antidepressants (SSRIs/SNRIs like venlafaxine or citalopram) โ well-studied and effective for hot flashes (note: some interact with tamoxifen, so the choice matters โ your physician will guide this).
- Gabapentin โ particularly helpful for night-time hot flashes and sleep.
For vaginal dryness, painful sex & urinary symptoms
This is the question I’m asked most anxiously, so hear this clearly:
- Non-hormonal first: regular vaginal moisturizers and lubricants for intimacy are completely safe and often very effective โ start here.
- Vaginal estrogen is generally considered safe, even for most breast cancer survivors. Because it works locally with minimal absorption into the bloodstream, the evidence does not show it increases breast cancer risk. For many survivors with symptoms that moisturizers can’t fix, it’s a reasonable option โ made as a shared decision with your oncologist. The one group that warrants extra individualized discussion is women on aromatase inhibitors, where the conversation is more nuanced.
Suffering in silence is not required. These symptoms are treatable, and relief is part of good survivorship care.
The bottom line
- A diagnosis is frightening but highly treatable โ your plan is built specifically for your cancer by a team, combining surgery, radiation, and systemic therapy as needed.
- Endocrine therapy is the cornerstone for HR-positive cancer: tamoxifen (pre- or post-menopausal; protects bone but small clot/uterine risks) vs. aromatase inhibitors (postmenopausal; slightly more effective but cause bone loss and joint aches). The right choice is individual.
- Not everyone needs chemo โ gene-expression testing (e.g., Oncotype DX) now spares many women from it; it’s most clearly needed for triple-negative, HER2-positive, or higher-stage disease.
- Protect your bones โ DEXA monitoring, calcium/vitamin D, strength training, and bone-protecting medication when indicated, especially on an AI.
- You don’t have to suffer through menopausal symptoms: effective non-hormonal options exist for hot flashes (fezolinetant, elinzanetant, SSRIs/SNRIs, gabapentin), and vaginal estrogen is generally safe even for most survivors.
A breast cancer diagnosis changes your life โ but with today’s treatments, the overwhelming likelihood is that you will come through it. And you deserve to feel well along the way.
If you or someone you love is newly diagnosed and feeling overwhelmed by the decisions ahead โ or struggling with treatment side effects no one has helped you manage โ please know that support exists, and you don’t have to navigate it alone.
Coming next โ We’ll close out our month of Breast Cancer Awareness posts.
Part 4: Life after breast cancer: thriving, not just surviving.
Selected References
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with ER-positive early breast cancer treated with ovarian suppression: patient-level meta-analysis of 7030 women. Lancet Oncol. 2022;23(3):382โ392.
- EBCTCG. Aromatase inhibitors versus tamoxifen in postmenopausal women: meta-analysis of the randomized trials. Lancet. 2015;386:1341โ1352.
- Sparano JA, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer (TAILORx / Oncotype DX). N Engl J Med. 2018;379:111โ121.
- Bone loss and aromatase inhibitors: management and bone-modifying agents in early breast cancer (review). PMC2361688.
- Komen / Breast Cancer Research. Treating menopausal symptoms in breast cancer survivors โ non-hormonal options and vaginal estrogen safety. 2025.
- FDA approval of elinzanetant (Lynkuet), October 2025 โ first non-hormonal agent shown to reduce VMS in women on tamoxifen or aromatase inhibitors; SKYLIGHT (fezolinetant) phase 3 trials.
- Vaginal estrogen in breast cancer survivors: systematic reviews showing no demonstrated increase in recurrence, with individualized caution for concurrent aromatase inhibitor use. Am J Obstet Gynecol / Maturitas. 2024โ2026.
- The 2020 GSM position statement of The North American Menopause Society (local vaginal estrogen; minimal systemic absorption).
This article is for educational purposes and reflects the state of the evidence at the time of writing; it is not a substitute for individualized medical advice. Breast cancer treatment is highly personalized and directed by your oncology team; the options described may or may not apply to your situation. Decisions about endocrine therapy, chemotherapy, bone-protective treatment, and symptom management โ including any use of vaginal estrogen โ should be made together with your oncologist and care team in the context of your specific diagnosis and history. Report any abnormal vaginal bleeding, new breast changes, or concerning symptoms promptly.
